Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Korea’s Samsung And Biogen Idec Initiate JV For Global Biosimilars Development

This article was originally published in PharmAsia News

Executive Summary

The $300 million Korean joint venture gives Samsung a global stage but raises questions about its Rituxan biosimilars program.

You may also be interested in...



Samsung Will Develop Biosimilars For U.S. And EU, But Avoids Emerging Markets For Now

SEOUL - Samsung Biologics, which hopes to establish itself as a global contract manufacturer in a long journey to become a global biopharmaceutical company, said it will eventually try to sell its biosimilars in the U.S. and EU markets rather than emerging markets

Samsung Looks To Mirror Fellow Korean Pharma Celltrion's Path From CMO To Biosimilars Developer With Quintiles JV

SEOUL - South Korea's leading conglomerate Samsung Group is following in the footsteps of Korea's biosimilar front-runner Celltrion in beginning its biopharmaceutical journey as a contract manufacturing organization via a joint venture announced Jan. 25 with multinational contract research organization Quintiles Transnational Corp.

Nichi-Iko Takes Share Of Korean Biosimilar Firm, Gains Japanese Rights For Remicade And Herceptin Generics

TOKYO - Nichi-Iko has upped its capability to bring biosimilars to the Japanese market, buying a 33 percent stake in South Korean biosimilar firm Aprogen, giving the Japanese generics maker exclusive rights to Aprogen products in Japan

Topics

Related Companies

UsernamePublicRestriction

Register

OM014142

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel